title: [Ovarian yolk sac tumour: general review].
abstract: Ovarian yolk sac tumour (OYST) is a very rare malignancy arising most often in young women. Preoperative clinical, biological (alpha-foetoprotein) and radiological findings should help to establish the diagnosis of OYST, in order to propose adequate surgical treatment. The aim of surgery is to remove the primary tumour, to obtain an accurate histological diagnosis and to assess the disease extent. In young women, fertility-sparing surgery should be performed, in order to preserve the possibility of pregnancy later on. Chemotherapy has substantially modified the prognosis of these tumours, and practically all patients will be cured. The overall 5-year survival rate is 94% when patients are treated with BEP chemotherapy. Depending on the clinical situation, two to four cycles of the BEP regimen should be administered after surgery. Identification of prognostic factors may help to propose risk-adapted treatment in order to increase the cure rate in patients with a poor prognosis and to decrease toxicity in patients with a low risk of relapse. Fertility preservation represents a major objective in women treated for OYSTs.
authors.affiliation: Institut Gustave-Roussy, Villejuif, France.
authors.forename: Caroline
authors.initials: C
authors.lastname: Even
authors.forename: Catherine
authors.initials: C
authors.lastname: Lhommé
authors.forename: Pierre
authors.initials: P
authors.lastname: Duvillard
authors.forename: Philippe
authors.initials: P
authors.lastname: Morice
authors.forename: Corinne
authors.initials: C
authors.lastname: Balleyguier
authors.forename: Patricia
authors.initials: P
authors.lastname: Pautier
authors.forename: Frédéric
authors.initials: F
authors.lastname: Troalen
authors.forename: Thibault
authors.initials: T
authors.lastname: de La Motte Rouge
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000379:methods; D018240:Endodermal Sinus Tumor / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D005260:Female; D005298:Fertility; D006801:Humans; D035583:Rare Diseases / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate; D013997:Time Factors; D000509:alpha-Fetoproteins / Q000032:analysis
chemical_list: D000509:alpha-Fetoproteins